Effectiveness of Action Observation Therapy in Stroke Patients

December 3, 2025 updated by: KTO Karatay University

Investigating the Effectiveness of Action Observation Therapy Applied in Addition to Conventional Treatment in Stroke Patients

The goal of this clinical trial is to learn the effectiveness of action observation therapy in patients with stroke.

The main questions it aims to answer are:

Is action observation therapy an effective method in stroke patients?

Researchers will compare the results of two action observation-based exercises (home program) with conventional exercise to see whether action observation therapy works in the rehabilitation of stroke patients.

Participants:

Participants in one group will do action observation-based exercise (home plus conventional exercise for 24 sessions, Patients in the control group will only undergo conventional exercise in addition to routine treatment.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Individuals with chronic stroke will be included in this study. Participants will be randomly divided into two groups, and patients in both groups will continue their routine treatments.

Patients in the control group will only undergo conventional exercise. Patients in the study group will be given a home exercise program in addition to conventional treatment. However, patients will be asked to first watch the video of each exercise in this program and then perform the exercise.

Patients will be asked to perform the exercises 3 days a week for 8 weeks. Evaluations will be made twice, before the exercise program application begins and after the sessions are completed.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Stroke patients in the chronic phase (more than 6 months have passed since the stroke)
  • Patients over 40 years of age
  • Patients who can stand and walk independently (including those using walking aids)

Exclusion Criteria:

  • Additional disease (neurological, orthopedic, etc.) that may affect motor performance and balance.
  • Patients with communication problems
  • Patients with mental problems (mini-mental test score <23)
  • Patients aged 85 and over

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Action Observation Therapy-Experimental Group
Patients will be asked to watch the exercises before doing them. For each exercise, patients will first watch the relevant video and do the exercise after the video ends.
Other: Action Observation Therapy-Experimental Group
Patients will be asked to watch the exercises before doing them.For each exercise, patients will first watch the relevant video and do the exercise after the video ends.
Active Comparator: Conventional Exercises-Control Group
Patients will be subjected to conventional exercise only.
Other: Conventional Exercises-Control Group
Patients will be subjected to conventional exercise only.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
2 minute walk test
Time Frame: The evaluation will be applied at the baseline and after study completion, an average of 2 months.
Patients will be asked to walk 30 meters long on a flat surface for 2 minutes. When the time is up, the distance the patient can walk will be recorded.
The evaluation will be applied at the baseline and after study completion, an average of 2 months.
Berg Balance Scale
Time Frame: The evaluation will be applied at the baseline and after study completion, an average of 2 months.
The Berg Balance Scale is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of funcion.
The evaluation will be applied at the baseline and after study completion, an average of 2 months.
Fugl-Meyer Assessment
Time Frame: The evaluation will be applied at the baseline and after study completion, an average of 2 months.
The FMA motor assessments for the lower extremity (minimum score:0 and maximum score 34 points) will be applied. A higher score means the patient's motor movements are better.
The evaluation will be applied at the baseline and after study completion, an average of 2 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

KTO Karatay University

Investigators

  • Principal Investigator: Osman Karaca, PhD, KTO Karatay University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 16, 2024

Primary Completion (Actual)

September 30, 2025

Study Completion (Actual)

September 30, 2025

Study Registration Dates

First Submitted

July 8, 2024

First Submitted That Met QC Criteria

July 8, 2024

First Posted (Actual)

July 15, 2024

Study Record Updates

Last Update Posted (Actual)

December 10, 2025

Last Update Submitted That Met QC Criteria

December 3, 2025

Last Verified

October 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KaratayUO3

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Action Observation Therapy-Experimental Group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe